Abstract 17074: Plasma Levels of Soluble Neprilysin Do Not Fluctuate in the Acute Phase of Decompensated Heart Failure: Independent of Cardiac Factors
Hiroyuki Takahama(Tohoku University), Toshihisa Anzai(Hokkaido University), Satoshi Yasuda(Tohoku University), Hideaki Kanzaki(National Cerebral and Cardiovascular Center), Naoto Minamino(National Cerebral and Cardiovascular Center), Yasuhiro Hamatani(National Cerebral and Cardiovascular Center), Akiko Ogai, Atsushi Okada(National Cerebral and Cardiovascular Center), Kenji Kangawa(National Cerebral and Cardiovascular Center), Makoto Amaki(National Cerebral and Cardiovascular Center), Masafumi Kitakaze(Hanwa Memorial Hospital), Takuya Hasegawa(National Cerebral and Cardiovascular Center), Shin Ito(National Cerebral and Cardiovascular Center), Yasuo Sugano(keiyu Hospital)
Circulation
November 14, 2017
Cited by 0
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Plasma Brain Natriuretic Peptide as a Prognostic Indicator in Patients With Primary Pulmonary Hypertension
|Circulation|2000|880
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
|Nature Medicine|2002|722
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
|Circulation Journal|2019|582
Plasma Brain Natriuretic Peptide Levels Increase in Proportion to the Extent of Right Ventricular Dysfunction in Pulmonary Hypertension
|Journal of the American College of Cardiology|1998|578